Jump to top menu Jump to main menu Jump to content
Department

Dermatology

Our mission is to perform clinically relevant research. We aim to improve the diagnosis, treatment and outcome of patients with dermatological conditions. Our research includes clinical, epidemiological, cost-effectiveness, qualitative and translational research to detect conditions at early stages, improve treatment and prognosis, and change public health policies.

About our department

Our research

Erasmus MC has the largest academic dermatology department in the Netherlands. All the principal investigators combine clinics with research. This combination enables us to identify clinically relevant questions and motivates us to translate the gained research insights back to the patient. This interaction between care and research is the core of the department’s research.

This close relationship implies that we have a strong interest in biobanks of diseases of interest, use routine collected (clinical, pharmacy, claims) data and are involved in many clinical trials (preferably with a laboratory component). We are also involved in the large population based cohorts in Rotterdam (Generation R and Rotterdam Study).

The research methodologies best development in the department are epidemiology (in the broadest sense), clinical research and translational research, especially in immunology and oncology.  To achieve a high standard of research, we collaborate in institutional, national and international multidisciplinary consortia and networks. The department is recognized as one of the leading centers for dermato-epidemiology globally.

Principal Investigators

Research Lines

Projects

Publications

Oncology:

  • Wakkee M, van Egmond S, Louwman M, Bindels P, van der Lei J, Nijsten T, Hollestein L. Opportunities for improving the efficiency of keratinocyte carcinoma care in primary and specialist care: Results from population-based Dutch cohort studies. Eur J Cancer. 2019 Aug;117:32-40.
  • van Lee CB, Roorda BM, Wakkee M, Voorham Q, Mooyaart AL, de Vijlder HC, Nijsten T, van den Bos RR. Recurrence rates of cutaneous squamous cell carcinoma of the head and neck after Mohs micrographic surgery vs. standard excision: a retrospective cohort study. Br J Dermatol. 2019 Aug;181(2):338-343.
  • Verkouteren JAC, Smedinga H, Steyerberg EW, Hofman A, Nijsten T. Predicting the Risk of a Second Basal Cell Carcinoma. J Invest Dermatol. 2015 Nov;135(11):2649-2656.

Hidradenitis suppurativa:

  • Vossen ARJV, Ardon CB, van der Zee HH, Lubberts E, Prens EP. The anti-inflammatory potency of biologics targeting tumour necrosis factor-α, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo study. Br J Dermatol. 2019 Aug;181(2):314-323.
  • Kimball AB, Kerdel F, Adams D, Mrowietz U, Gelfand JM, Gniadecki R, Prens EP, Schlessinger J, Zouboulis CC, van der Zee HH, Rosenfeld M, Mulani P, Gu Y, Paulson S, Okun M, Jemec GB. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012 Dec 18;157(12):846-55.

Atopic Dermatitis

  • de Wijs LEM, Bosma AL, Erler NS, Hollestein LM, Gerbens LAA, Middelkamp-Hup MA, Kunkeler ACM, Nijsten TEC, Spuls PI, Hijnen DJ. Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data. Br J Dermatol. 2019.

  • Totté JEE, Pardo LM, Fieten KB, Vos MC, van den Broek TJ, Schuren FHJ, Pasmans SGMA. Nasal and skin microbiomes are associated with disease severity in paediatric atopic dermatitis. Br J Dermatol. 2019 Oct;181(4):796-804.
  • Hu C, Nijsten T, Pasmans SGMA, de Jongste JC, Jansen PW, Duijts L.Associations of eczema phenotypes with emotional and behavioural problems from birth until school age. The Generation R Study. Br J Dermatol. 2019 Dec;181(6):1190-1197

Collaborations

 Research line: Oncology

  • The genetic consortium on squamous cell carcinoma, involving Decode Iceland, 23andMe (Stanford University) and the Nurse Health Study (Indiana University).
  • The international pharmaco-epidemiology Keracon consortium, to study the effects of common drugs on skin cancer development and prevention.
  • Public Health England to develop prediction and staging models for SCC.
  • The University of Nottingham to collaborate on Raman spectrometry research.
  • OCOMEN, an international collaboration initiated by the Erasmus MC for outcome measures on congenital nevi.
  • The SKIN European Reference Network.

Research line: Eczema

  • We play active roles in the International Society of Atopic Dermatitis (ISAD), the International Eczema Council (IEC) and the EADV Task Force for Atopic Dermatitis (ETFAD) to improve patient care (e.g., the development of new guidelines).
  • We work with Sanofi/Regeneron, an international advisory board for children.
  • We work with the European Academy of Allergy and Clinical Immunology Task Force Group on High Altitude Treatment.
  • We participate in many international, multi-centre, randomized and controlled trials with new biologics (e.g., Abbvie, LEO Pharma, Novartis, UCB and Regeneron).
  • We participate in the SKIN European Reference Network for Netherton syndrome and ichthyosis, also in relation to atopy.
  • We collaborate with other international cohorts in Generation R.

Research line: Hidradenitis suppurativa

  • The Pasteur Institute (Paris, France) and the University of Copenhagen (Denmark) on studies on the microbiome, because of their international expertise in HS and the skin microbiome.
  • The University of Michigan's Department of Dermatology on the molecular dissection of HS inflammation.
  • The SKIN European Reference Network to study and treat rare syndromic variants of HS in a European collaboration.
  • The European Hidradenitis Suppurativa Foundation. This global network of HS specialist centres works with similar databases to facilitate fast and collaborative research.
  • The European EADV Task Force for HS, Acne and Rosacea, to study HS in a European collaboration.
  • European Guidelines on HS.
  • Multiple international, multicentre, randomized and controlled trials with new anti-inflammatory biologics (e.g., Abbvie, InflaRX, Novartis, Janssen and UCB).

Vacancies

News, events and awards

Awards and grants

Prizes

R.Waalboer-Spuij received the prize for the best publication from the Dutch Society of PsychoDermatology in 2018 for his publication: ‘Development and Validation of the Basal and Squamous Cell Carcinoma Quality of Life Questionnaire’.

 

Grants

2020

Sanofi

Dutch Keratinocyte Cancer Collaborative

€ 808.775

 

2019

Health Holland

Early stage melanoma: who is at risk of distant metastasis?

€ 391.540

 

Mininster van volksgezondheid

ZiN-ZonMW en aanvullend verbandpakfabrikanten

Voorwaardelijk toelatingstraject: Effectiviteit van antibacteriële verbandkleding bij matig tot ernstig constitutioneel eczeem. Start 2019

€ 400.000 + € 189.000

 

2018

Canadian Dermatology Foundation

Anti-hypertensive drugs and risk of keratinocyte cancer: a population-based study

$ 55.000

 

Zon Mw

GGG Personalised Medicine - Use of the NMF biomarker as predictive diagnostic for effective use of cyclosporine in the treatment of eczema.

€ 500.000

 

Pierre Fabre 

Long term effects of beta blocker treatment in children with hemangioma

€ 650000

 

Micreos

Atopic dermatitis micriobiome and skin barrier

€ 200000

 

2017

Open grant Abbvie 2017-2020 

To standarise and improve hidradenitis suppurativa care in southwest region of the Netherlands

€ 235.000

Micreos

Skin and immune dysregulation

€ 257.000

 

Micreos

Verlenging Maas trial 

€ 191.000 

 

Novartis

DermHome (www.huidhuis.nl): Care plan Urticaria

€ 43.000 

 

Micreos

Skin and immune dysregulation

€ 257.000 

 

2016

Netherlands Federation of University Medical Centres (NFU)

Basal Cell Carcinoma Follow-Up Study (B-FUS)

€ 200.000

 

2015

National Health Care Institute Netherlands (Zorginstituut Nederland [ZiNL])

Wise follow-up care for patients who are treated for non-melanoma skin cancer and actinic keratosis

€ 180.000